SNORA9: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORA9

NCBI ID: G677798

SNORA9

Other Name(s): small nucleolar RNA, H/ACA box 9 | Small nucleolar RNA, H/ACA box 9 | ACA9 | SNORA9A

SNORA9: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to interact with the protein responsible for loading the nuclear DNA onto the nuclear chromosome, known as histone H3. Histone H3 is a protein composed of nine histone subtypes, of which the ninth histone H3 is also called SNORA9. SNORA9 plays an important role in gene expression and regulation and is also a potential drug target for many diseases. This article will introduce the structure, function, interactions and possibility of SNORA9 as a drug target.

Secondary structure of SNORA9

The molecular weight of SNORA9 is 28.9 kDa, which is mainly composed of two subunits: N-terminal 伪-helix and C-terminal 尾-sheet. The N-terminal 伪-helix is 鈥嬧?媍omposed of three 伪-helical units, and the secondary structure of the 伪-helix is 鈥嬧?媍omposed of three helical axes connected by three 尾-hydrogen bonds. The C-terminal 尾-sheet consists of two 尾-helical units connected by 尾-hydrogen bonds. In addition, the secondary structure of SNORA9 also consists of a free 伪-helical unit and a free 尾-helical unit located outside the N-terminus and C-terminus.

SNORA9 interaction

The interaction of SNORA9 is mainly achieved through its binding to histone H3. Histone H3 is a protein mainly composed of histone 伪, 尾, 纬 and 未 subunits. The binding of SNORA9 to histone H3 is a key step in SNORA9's gene expression and regulation.

The binding of SNORA9 to histone H3 is achieved by the interaction between the N-terminus of SNORA9 and the C-terminus of histone H3. The N-terminus of SNORA9 contains a special domain called the N-terminal 伪-helix, which is a complementary structure to the 伪-helix. The C-terminus of histone H3 contains a special domain called the C-terminal 伪-helix, which is also a complementary structure to the 伪-helix. The binding between these two domains is connected by three 尾 hydrogen bonds, thus forming the binding between SNORA9 and histone H3.

SNORA9 functions

SNORA9 plays an important role in gene expression and regulation. First, SNORA9 regulates gene expression by binding to histone H3. The binding of SNORA9 will cause the conformation of histone H3 to change, thereby affecting the binding of histone H3 to DNA. This interaction can lead to the regulation of gene expression, including gene expression level, gene expression pattern and gene expression time.

SNORA9 also regulates the cell cycle by binding to histone H3. The binding of SNORA9 will cause the conformation of histone H3 to change, thereby affecting the binding of histone H3 to DNA. This interaction can lead to cell cycle regulation, including cell cycle timing, cell cycle progression, and cell cycle changes.

Pharmacological significance of SNORA9

SNORA9 is a molecule of pharmacological interest because its interactions and functions can directly affect gene expression and cell cycle. Because SNORA9 plays an important role in gene expression and regulation, it is a potential drug target. Currently, some studies are exploring SNORA9 as a possible treatment for certain diseases.

Protein Name: Small Nucleolar RNA, H/ACA Box 9

The "SNORA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets